Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/sdi.12108 | DOI Listing |
Publication Analysis
Top Keywords
erythropoeitin-stimulating agent
4
agent reduced
4
reduced chronic
4
chronic dialysis
4
dialysis patients?
4
patients? adjuvant
4
adjuvant therapies
4
therapies reduce
4
reduce erythropoiesis-stimulating
4
erythropoiesis-stimulating agent
4
Similar Publications
How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: Adjuvant therapies to reduce erythropoiesis-stimulating agent dose requirements.
Semin Dial
May 2014
Division of Kidney Diseases and Hypertension, Department of Medicine, North Shore University Hospital and Long Island Jewish Medical Center, Hofstra North Shore-LlJ School of Medicine, Great Neck, New York.
How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: The itsy bitsy anemia problem.
Semin Dial
May 2014
Renal Division, Brigham and Women's Hospital and Harvard Medical School Boston, Boston, Massachusetts.
How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: Can reduction of inflammation improve ESA dose response?
Semin Dial
May 2014
Division of Nephrology, Department of Medicine, University of Tennessee Health Science Center and Memphis VA Medical Center, Memphis, Tennessee.
How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: The "forgotten adjunct therapy": the link between ESA use and control of hyperparathyroidism in chronic kidney disease.
Semin Dial
May 2014
From Division of Nephrology, University Health Network, Toronto, Ontario, Canada.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!